Skip to main content
< Back
About
About the conference
App
Organisers & Partners
Latest updates
Press room
Registration
Venue 22
About the venue
Rooms
Call for abstracts
Programme 22
Tracks 22
Speakers 22
Side events 22
Subscribe
days
hours
minutes
seconds
Oral presentation
Presentations
Wednesday, 23 November
10:50
Oral presentation
5. Addressing substance use and related problems in reception settings in Europe
10:50
to
12:20
Insights zone 4 (I4)
Charlotte De Kock,
Klaudia Palczak
Oral presentation
6. Caregiving packages in conflict and humanitarian settings for prevention of substance use and other health and social consequences and for child protection and development
10:50
to
12:20
Insights zone 4 (I4)
Wadih Maalouf
Oral presentation
7. Understanding and Responding to Substance Use and Abuse in the Palestinian Refugee Camps inLebanon Prior to and During COVID-19 Times
10:50
to
12:20
Insights zone 4 (I4)
Marie Claire Van Hout
Oral presentation
3. Handbook on Addressing Substance Use Disorders in Humanitarian Settings – Access to Services for Displaced Populations and Host Communities in Acute and Protracted Emergencies
10:50
to
12:20
Insights zone 4 (I4)
Anja Busse
Oral presentation
1. Priorities for addressing substance use disorder in humanitarian settings
10:50
to
12:20
Insights zone 4 (I4)
M. Claire Greene
Oral presentation
2. Substance Use Among Populations Displaced by Conflict: Assessments, Findings, Recommendations
10:50
to
12:20
Insights zone 4 (I4)
Nadine Ezard
Oral presentation
Psychological reactance and adolescent cannabis use: the role of parental warmth and monitoring
10:50
to
12:20
Insights zone 2 (I2)
William Crano
Oral presentation
Embracing public health approaches to gambling? A review of global legislative and regulatory trends
10:50
to
12:20
Insights zone 2 (I2)
Daria Ukhova
Oral presentation
Attitudes towards alcohol policy in Europe; results of the alcohol survey in 33 European countries
10:50
to
12:20
Insights zone 2 (I2)
Jacek Moskalewicz
Oral presentation
New problems, new approaches: Actions for the case of non-substance addictions for adolescents and young adults
10:50
to
12:20
Insights zone 2 (I2)
Joana Alexandre
Oral presentation
2. Training of trainers package on FAS/FASD prevention
10:50
to
12:20
Central square 1 (C1)
Lidia Segura
Oral presentation
3. Piloting an evidence-based good practice intervention for reducing the risk of FASD
10:50
to
12:20
Central square 1 (C1)
Katarzyna Okulicz-Kozaryn
Oral presentation
1. Guidelines to reduce alcohol consumption in women of child-bearing age
10:50
to
12:20
Central square 1 (C1)
Carla Bruguera
Oral presentation
1. Annual incidence of substance-induced psychoses in Scandinavia from 2000 to 2016
10:50
to
12:20
Knowledge market 2 (K2)
Eline Borger Rognli
Oral presentation
2. Characteristics of incident substance-induced psychosis compared to incident first episode psychosis. A nationwide register-linkage study
10:50
to
12:20
Knowledge market 2 (K2)
Pihla Sassi
Oral presentation
3. Relapse rate of substance-induced psychosis and associated risk factors. A nationwide registerlinkage study
10:50
to
12:20
Knowledge market 2 (K2)
Heidi Taipale
Oral presentation
4. Substance-induced psychosis and later schizophrenia or bipolar disorder: transition rates and the role of infections
10:50
to
12:20
Knowledge market 2 (K2)
Jørgen G. Bramness
Oral presentation
5. Antipsychotic use and associating factors among persons with substance-induced psychosis and first-episode psychosis. A nationwide register-linkage study
10:50
to
12:20
Knowledge market 2 (K2)
Jeyaniroshan Jeyapalan
Oral presentation
A qualitative exploration of patient’s experience of mobile telephone-delivered Contingency Management (mCM) to promote adherence to supervised methadone in UK pharmacies
10:50
to
12:20
Knowledge market 3 (K3)
Carol-Ann Getty
Oral presentation
I don’t chase drugs anymore and I’m not dead': The Impact of Safer Opioid Supply Programs in Ontario Canada on Client’s Health and Drug Use
10:50
to
12:20
Knowledge market 3 (K3)
Rose Schmidt
Oral presentation
Delivering telemedicine to vulnerable people with opioid use disorder: Outcomes of a program co-constructed and implemented with a community-based harm reduction service in Montreal, Canada
10:50
to
12:20
Knowledge market 3 (K3)
Stine Hoj
Oral presentation
Access to their own drugs': Navigating the drawbacks and benefits of injectable hydromorphone and diacetylmorphine treatment in Vancouver, BC
10:50
to
12:20
Knowledge market 3 (K3)
Samara Mayer
Oral presentation
Treatment-seeking problem gamblers: characteristics of individuals who offend to finance gambling
10:50
to
12:20
Insights zone 3 (I3)
Amanda Roberts
Oral presentation
Characterizing habit formation in modern slot machine gambling
10:50
to
12:20
Insights zone 3 (I3)
Luke Clark
Oral presentation
A scoping review on cryptocurrency trading among young people and its association with gambling and mental health
10:50
to
12:20
Insights zone 3 (I3)
Benjamin Johnson
Oral presentation
Cue-reactivity and inhibitory control in behavioral addcitions: an overview of functional neuroimaging studies
10:50
to
12:20
Insights zone 3 (I3)
Kjell Büsche
Oral presentation
Changes in social work practice and support for people who use drugs during the Covid-19 pandemic – a case study of Malmö, Sweden
10:50
to
12:20
Central square 3 (C3)
Torkel Richert
Oral presentation
2. Individuals dying of overdoses related to pharmaceutical opioids differ from individuals dying of overdoses related to other substances
10:50
to
12:20
Knowledge market 1 (K1)
Svetlana Skurtveit
Oral presentation
3. Changes in primary cause of overdose deaths following liberalisations in opioid prescription practices and differences in overdose death correlates.
10:50
to
12:20
Knowledge market 1 (K1)
Linn Gjersing
Oral presentation
4. Fatal overdoses in a cohort of chronic pain patients
10:50
to
12:20
Knowledge market 1 (K1)
Aleksi Hamina
Oral presentation
Agreement between self-reported illicit drug use and biological samples: a systematic review and meta-analysis
10:50
to
12:20
Central square 2 (C2)
Chrianna Bharat
Oral presentation
Anti-doping knowledge and educational needs of Finnish pharmacists
10:50
to
12:20
Central square 2 (C2)
Jukka Koskelo
Oral presentation
The implementation of ultra-portable devices for analysis of illicit drug in drug checking service of the Canton of Vaud (Switzerland, CH)
10:50
to
12:20
Central square 2 (C2)
Emilia Gianola
Oral presentation
Characteristics of acute ecstasy-related toxicity in multiple Dutch medical settings, from 2009 through 2018
10:50
to
12:20
Central square 2 (C2)
Lonja Schurmann
Oral presentation
Metabolite profiling of synthetic cathinones: towards the identification of consumption biomarkers in forensic and clinical settings
10:50
to
12:20
Central square 2 (C2)
Alexandra Antunes
Oral presentation
Substance Use and Substance Use Disorders in relation to COVID-19: Qualitative Experience of Users in Jordan
10:50
to
12:20
Central square 3 (C3)
Mayyada Wazaify
Oral presentation
Overdose deaths and the COVID-19 pandemic in British Columbia, Canada
10:50
to
12:20
Central square 3 (C3)
Alexis Crabtree
Oral presentation
1. Characteristics of suicides among overdose deaths in Norway in 2016-2020
10:50
to
12:20
Knowledge market 1 (K1)
Hilde Marie Erøy Edvardsen
Oral presentation
Drug use and attitudes toward COVID-19 vaccination in a representative sample of undergraduate students
10:50
to
12:20
Central square 3 (C3)
Stelios Stylianou
Oral presentation
2. Medical use of cannabis and cannabinoids: an overview of evidence
10:50
to
12:20
Knowledge market 4 (K4)
Mafalda Pardal
Oral presentation
5. Treatment of cannabis-related problems in Europe: a typology and evidence overview
10:50
to
12:20
Knowledge market 4 (K4)
Daniel Feingold
Oral presentation
3. Cannabis-related effects and harms: a scientific overview
10:50
to
12:20
Knowledge market 4 (K4)
Jakob Manthey
Oral presentation
4. Harm reduction for cannabis related problems in Europe and beyond
10:50
to
12:20
Knowledge market 4 (K4)
Iciar Indave
Oral presentation
1. Global epidemiology of injecting drug use, HIV/HCV among people who inject drugs, and coverage of interventions to reduce drug-related harms
10:50
to
12:20
Main stage
Louisa Degenhardt
Oral presentation
2. Successful models for implementation of harm reduction programmes
10:50
to
12:20
Main stage
Monica Ciupagea
Oral presentation
3. How can we improve data and mobilise funding for harm reduction support globally?
10:50
to
12:20
Main stage
Keith Sabin
Oral presentation
4. Community advocacy and community-led monitoring to improve coverage and quality of services to reduce drug-related harms
10:50
to
12:20
Main stage
Judy Chang
Oral presentation
1. Gender-sensitive drug policy
10:50
to
12:20
Insights zone 1 (I1)
Gabriele Fischer
Oral presentation
2. Youth-centered drug policy
10:50
to
12:20
Insights zone 1 (I1)
Danya Fast
Oral presentation
3. Perspectives of people who use drugs on drug policy
10:50
to
12:20
Insights zone 1 (I1)
Mat Southwell
Oral presentation
Getting your addiction research published: seminar
10:50
to
12:20
Central square 4 (C4)
Richard Pates
12:20
Oral presentation
Alcohol consumption, impact of COVID-19 and alcohol-attributable disease burden: a global update
12:20
to
12:40
Insights zone 4 (I4)
Jürgen Rehm
12:30
Oral presentation
1. Community perspective on access to harm reduction
12:30
to
13:10
Insights zone 3 (I3)
Judy Chang
Oral presentation
2. Documenting Egypt’s adoption and upcoming rollout of OAT
12:30
to
13:10
Insights zone 3 (I3)
Raghda Algamil
Oral presentation
3. Introducing the WHO Consolidated guidelines for key populations
12:30
to
13:10
Insights zone 3 (I3)
Annette Verster
Oral presentation
4. Introducing the UNODC-WHO OAT Operational tool and training package
12:30
to
13:10
Insights zone 3 (I3)
Monica Ciupagea
12:40
Oral presentation
Global alcohol action plan 2020-2030
12:40
to
12:50
Insights zone 4 (I4)
Vladimir Poznyak
12:50
Oral presentation
European framework for action on alcohol 2022-2025
12:50
to
13:00
Insights zone 4 (I4)
Carina Ferreira-Borges
13:20
Oral presentation
4. The Impact of the Russian Invasion of Ukraine on Needle and Syringe Distribution by Harm Reduction Organizations
13:20
to
14:50
Insights zone 4 (I4)
Benjamin Nikitin
Oral presentation
1. Equitable substance use treatment for migrants, refugees and ethnic minorities: An emerging research domain
13:20
to
14:50
Insights zone 4 (I4)
Inês Hasselberg
Oral presentation
2. Substance use disorders in refugee and migrant groups in Sweden: A nationwide cohort study of 1.2 million people
13:20
to
14:50
Insights zone 4 (I4)
Samantha Harris
Oral presentation
5. Services for vulnerable Migrants who use Drugs in the EU (SEMID-EU)
13:20
to
14:50
Insights zone 4 (I4)
Machteld Busz
Oral presentation
3. Smartphone-based addiction prevention for young refugees: results of a feasibility study
13:20
to
14:50
Insights zone 4 (I4)
Lina-Sophia Falkenberg
Oral presentation
1. ABC-Training: A New Proposition-Based Variety of Cognitive Bias Modification. Theoretical Background and Initial Results.
13:20
to
14:50
Central square 1 (C1)
Reinout W. Wiers
Oral presentation
2. Phenotyping Individuals with Alcohol Use Disorder: Implications for Precision Medicine and Predicting Non-Abstinent Recovery from Alcohol Use Disorder
13:20
to
14:50
Central square 1 (C1)
Katie Witkiewitz
Oral presentation
3. Examining a Brief Measure and Observed Cutoff Scores to Identify Reward and Relief Drinking Profiles: Psychometric Properties and Pharmacotherapy Response
13:20
to
14:50
Central square 1 (C1)
Victoria R. Votaw
Oral presentation
Assessing the impact of COVID-19 and associated control measures on interventions to prevent drug-related harm among people who inject drugs in Scotland
13:20
to
14:50
Knowledge market 3 (K3)
Kirsten Trayner
Oral presentation
The Contribution of Unstable Housing to HIV and Hepatitis C Virus Transmission Among People Who Inject Drugs Globally, Regionally, and at Country Level: A Modelling Study
13:20
to
14:50
Knowledge market 3 (K3)
Jack Stone
Oral presentation
The effectiveness of low dead space syringes for reducing the risk of hepatitis C virus acquisition among people who inject drugs - findings from a national survey in UK
13:20
to
14:50
Knowledge market 3 (K3)
Peter Vickerman
Oral presentation
Global incidence of hepatitis C virus (HCV) and HIV infection among people who inject drugs: A systematic review and meta-analysis
13:20
to
14:50
Knowledge market 3 (K3)
Adelina Artenie
Oral presentation
Online gambling and associated harms during the COVID-19 pandemic: A population study
13:20
to
14:50
Insights zone 3 (I3)
Sylvia Kairouz
Oral presentation
Online gambling and F2P games in Canada: portrait and trends
13:20
to
14:50
Insights zone 3 (I3)
Annie-claude Savard
Oral presentation
Problem gambling among European adolescents: potential risk of gambling products and online gambling
13:20
to
14:50
Insights zone 3 (I3)
Elisa Benedetti
Oral presentation
Cryptocurrency trading as behavioral addiction: cross-sectional and longitudinal perspective from Finland
13:20
to
14:50
Insights zone 3 (I3)
Atte Oksanen
Oral presentation
5. The U.S. Cannabis Policy Scale: Moving Beyond Dichotomous Measures to Evaluate Impacts of Liberalization Policies on Cannabis and Other Substance Use Outcomes
13:20
to
14:50
Knowledge market 1 (K1)
Rosalie Pacula
Oral presentation
2. Measuring the impacts of a new cannabis regulation in Luxembourg: the need for valid data collection methods
13:20
to
14:50
Knowledge market 1 (K1)
Nadine Berndt
Oral presentation
3. The Swiss pilot trials with cannabis – evaluation after one year
13:20
to
14:50
Knowledge market 1 (K1)
Maya Ackermann
Oral presentation
4. The Dutch closed cannabis supply chain experiment: background, design of the evaluation study and challenges
13:20
to
14:50
Knowledge market 1 (K1)
Margriet van Laar
Oral presentation
1. Prevention Science and the Professionalization of Prevention Practice
13:20
to
14:50
Main stage
Zili Sloboda
Oral presentation
3. Training the Prevention Workforce-Future Prevention Workforce
13:20
to
14:50
Main stage
Michal Miovsky
Oral presentation
2. International Credentialling
13:20
to
14:50
Main stage
Marissa Carlson
Oral presentation
Digital technologies to prevent drug overdoses. A UK perspective
13:20
to
14:50
Central square 3 (C3)
Alberto Oteo
Oral presentation
Feasibility and efficacy of the S-Check App to change help seeking behaviour of people who use methamphetamine
13:20
to
14:50
Central square 3 (C3)
Krista Siefried
Oral presentation
2. Design and Testing of an Aftercare Mobile App for Substance Use Among Young Adults: An Interdisicplinary Approach in Denmark
13:20
to
14:50
Insights zone 2 (I2)
Adriana del Palacio-Gonzalez
Oral presentation
3. A guided digital intervention to reduce cannabis use: the ICan randomized controlled trial in the Netherland
13:20
to
14:50
Insights zone 2 (I2)
Marleen Olthof
Oral presentation
4. Boozebuster: A Mobile Intervention to Promote Low-Risk Drinking Habits in Young Adults –preliminary results
13:20
to
14:50
Insights zone 2 (I2)
Mieke Schulte
Oral presentation
1. Guided smartphone-based treatment for patients in opioid maintenance treatment in Iran -transdiagnostic treatment for substance use and common mental disorders
13:20
to
14:50
Insights zone 2 (I2)
Michael Schaub
Oral presentation
1. Developing a functional taxonomy for Digital Health Interventions in Addiction Services
13:20
to
14:50
Central square 2 (C2)
Joseph Tay Wee Teck
Oral presentation
3. Immersive Virtual Reality in the Assessment and Treatment of Addictive Disorders: Current Status and Future Perspectives
13:20
to
14:50
Central square 2 (C2)
Simon Langener
Oral presentation
Discontinuing chronic benzodiazepine use for insomnia with blended care: results of a pragmatic cluster-RCT
13:20
to
14:50
Central square 3 (C3)
Kristien Coteur
Oral presentation
A cluster randomised controlled trial of an eHealth intervention to prevent multiple lifestyle risk behaviours among Australian adolescents: Results from the Health4Life Study
13:20
to
14:50
Central square 3 (C3)
Katrina Champion
Oral presentation
5. Estimating the costs of the criminal justice system
13:20
to
14:50
Knowledge market 4 (K4)
Francesco Fabi
Oral presentation
1. Overview of the updated ECDC/EMCDDA guidance on the prevention and control of infectious diseases among people who inject drugs
13:20
to
14:50
Networking zone 3 (N3)
Anne Bergenstrom,
Janelle Sandberg
Oral presentation
2. Effectiveness of drug treatment, needle and syringe programmes and drug consumption rooms in the prevention of blood-borne viruses among people who inject drugs – updated evidence from reviews of empirical and mathematical modelling studies
13:20
to
14:50
Networking zone 3 (N3)
Matthew Hickman
Oral presentation
3. Enhancing the HCV care cascade among people who inject drugs: a systematic review and considerations from an expert panel
13:20
to
14:50
Networking zone 3 (N3)
Ilonka Horváth
Oral presentation
1. Drug laws indicators through the leximetric approach and relationship with effectiveness: the example of Italy in the period 1991-2018
13:20
to
14:50
Knowledge market 4 (K4)
Carla Rossi
Oral presentation
2. Hospitalization risk profile of opioids users
13:20
to
14:50
Knowledge market 4 (K4)
Giada Minelli
Oral presentation
3. Using Supply Indicators in the Evaluation of Drug Supply Reduction – Challenges and Opportunities
13:20
to
14:50
Knowledge market 4 (K4)
Nicola Singleton
Oral presentation
4. Estimating the size of the of illicit drug market – a critical review
13:20
to
14:50
Knowledge market 4 (K4)
Robin Udrisard
Oral presentation
1. Overdose prevention and treatment implications of fentanyl use in the United States
13:20
to
14:50
Central square 4 (C4)
Alexander Walley
Oral presentation
2. Digital Health Interventions: Petiscos from clinical practice
13:20
to
14:50
Central square 2 (C2)
Roya Vaziri
Oral presentation
2. Fentanyl related deaths and fentanyl acute toxicity presentations at emergency Departments in Europe, 2010-2020
13:20
to
14:50
Central square 4 (C4)
Peter Heudtlass
Oral presentation
3. High drug-related death mortality in Finland – special focus on young adults and teenagers
13:20
to
14:50
Central square 4 (C4)
Prikko Kriikku
Oral presentation
4. Intentional overdoses and associated mental health challenges, an overlooked sub-population of overdoses
13:20
to
14:50
Central square 4 (C4)
Thomas Clausen
15:00
Oral presentation
5. Changing drug market requires new priorities for Moldova’s law enforcement authorities
15:00
to
16:30
Insights zone 4 (I4)
Vladislav Cojuhari
Oral presentation
2. Lebanon: responding to drug market changes in crisis situation
15:00
to
16:30
Insights zone 4 (I4)
Zeinab Abbas
Oral presentation
4. Key developments in drug markets of Eastern European Neighbourhood Policy (ENP) countries
15:00
to
16:30
Insights zone 4 (I4)
Daan Van der Gouwe
Oral presentation
1. Key developments in drug markets of North Africa and Middle East
15:00
to
16:30
Insights zone 4 (I4)
Emadeddin Badi
Oral presentation
3. Key developments in drug markets of Western Balkans
15:00
to
16:30
Insights zone 4 (I4)
Robert Patrancus,
Katerina Skarupova
Oral presentation
Temporal changes in alcohol consumption associated with the COVID-19 interventions in Belgium: a wastewater-based approach
15:00
to
16:30
Central square 1 (C1)
Maarten Quireyns
Oral presentation
Impacts of changes in alcohol consumption patterns during the first 2020 COVID-19 restrictions for people with and without mental health and neurodevelopmental conditions: A cross sectional study in 13 countries
15:00
to
16:30
Central square 1 (C1)
Gail Gilchrist
Oral presentation
Severe COVID-19 cases among patients admitted to treatment for alcohol and drug use disorders in Catalonia
15:00
to
16:30
Central square 1 (C1)
Jorge Palacio-Vieira
Oral presentation
Disentangling the 'COVID-19 alcohol paradox': reasons for changes in alcohol-specific disease burden during the COVID-19 pandemic in Germany
15:00
to
16:30
Central square 1 (C1)
Jakob Manthey
Oral presentation
1. What do we mean by psychiatric comorbidity or dual disorders?
15:00
to
16:30
Knowledge market 2 (K2)
Marta Torrens
Oral presentation
2. Impact of Covid19 on mental health and drug use: main findings from the EMCDDA trendspotter study
15:00
to
16:30
Knowledge market 2 (K2)
Franca Beccaria
Oral presentation
3. Psychiatric comorbidity in the European countries: prevalence and models of care
15:00
to
16:30
Knowledge market 2 (K2)
Francina Fonseca
Oral presentation
4. The dual diagnosis inpatient and outpatient treatment program in Ljubljana: practical implementatio
15:00
to
16:30
Knowledge market 2 (K2)
Nusa Segrec,
Andrej Kastelic
Oral presentation
Fear of inpatient opioid withdrawal: Addressing a modifiable barrier to health-care access for people who use illicit opioids.
15:00
to
16:30
Knowledge market 3 (K3)
Magdalena Harris
Oral presentation
Analysis of drugs in used syringes from sentinel European cities, 2020
15:00
to
16:30
Knowledge market 3 (K3)
Thomas Seyler
Oral presentation
The impact of opioid agonist treatment on hospitalisations for injecting-related diseases: a retrospective data linkage study
15:00
to
16:30
Knowledge market 3 (K3)
Samantha Colledge-Frisby
Oral presentation
1. Quality Assurance Tools: Improving Coverage, Accessibility and Quality of Drug Use Disorder Treatment
15:00
to
16:30
Knowledge market 1 (K1)
Anja Busse
Oral presentation
4. Key factors for a successful implementation of Quality Standards in Drug Demand Reduction – a Delphi Study
15:00
to
16:30
Knowledge market 1 (K1)
Rafaela Rigoni
Oral presentation
2. Further ENhancing the Implementation of Quality Standards in drug demand reduction across Europe (FENIQS-EU) project – study objectives and first realisations
15:00
to
16:30
Knowledge market 1 (K1)
Dijana Jerkovic
Oral presentation
3. State of the Art of Quality Standards implementation in drug demand reduction in Europe
15:00
to
16:30
Knowledge market 1 (K1)
Martina Feric
Oral presentation
5. An inspiring practice example of Quality Standards implementation: the Spanish Good Practice inDemand Reduction Portal (PBBPP)
15:00
to
16:30
Knowledge market 1 (K1)
Alba González-Roz
Oral presentation
1. Convergences in the psychology of behavioral addictions
15:00
to
16:30
Main stage
Matthias Brand
Oral presentation
2. Convergences in the neurobiology of behavioral addictions
15:00
to
16:30
Main stage
Marc N. Potenza
Oral presentation
3. Convergences in the treatment of behavioral addictions
15:00
to
16:30
Main stage
Susana Jiménez-Murcia,
Fernando Fernández-Aranda,
Roser Granero
Oral presentation
4. Convergences in behavioral addiction policies
15:00
to
16:30
Main stage
Sophia Achab
Oral presentation
Mortality consequences of misuse of psychoactive prescription drugs in Portugal - the MisuMedPT project
15:00
to
16:30
Central square 3 (C3)
Ana Araújo
Oral presentation
5. International cooperation to address global public health harms caused by novel psychoactive substances while protecting access to medicines
15:00
to
16:30
Central square 2 (C2)
Dilkushi Poovendran
Oral presentation
1. Early warning on emerging drug threats at the international level – opportunities and challenges
15:00
to
16:30
Central square 2 (C2)
Martin Raithelhuber
Oral presentation
2. Global markets, glocal threats: Early warning, preparedness, and response to new psychoactive substances in Europe
15:00
to
16:30
Central square 2 (C2)
Michael Evans-Brown
Oral presentation
3. Early Warning Systems are Critical to Drug Control Strategies to Protect Public Health and Safety
15:00
to
16:30
Central square 2 (C2)
Luli R. Akinfiresoye,
Terrence L. Boos
Oral presentation
4. NPS Discovery: An Open Access Early Warning System for the United States
15:00
to
16:30
Central square 2 (C2)
Barry K. Logan
Oral presentation
Utilising data linkage to describe and explore mortality among a retrospective cohort of individuals admitted to residential substance use treatment.
15:00
to
16:30
Central square 3 (C3)
Tisdale Calvert
Oral presentation
It is logically not possible to quantify the number of indirect deaths
15:00
to
16:30
Central square 3 (C3)
Alfred Uhl
Oral presentation
Mortality and Morbidity in Patients in Opioid Maintenance Treatment
15:00
to
16:30
Central square 3 (C3)
Roman Gabrhelík
Oral presentation
Trends in mortality from alcohol, opioid, and combined alcohol and opioid poisonings by sex, educational attainment and race and ethnicity for the United States 2000-2018.
15:00
to
16:30
Central square 3 (C3)
Charlotte Buckley
Oral presentation
1. Twenty-one years of operation at the Uniting Sydney Medically Supervised Injecting Centre (MSIC) Australia
15:00
to
16:30
Insights zone 3 (I3)
Marianne Jauncey
Oral presentation
2. The rapid expansion of DCRs/SIFs in Canada in the context of a public health emergency
15:00
to
16:30
Insights zone 3 (I3)
Jane Buxton
Oral presentation
3. Denmark: A successful case study in community advocacy culminating in several sanctioned SIFs
15:00
to
16:30
Insights zone 3 (I3)
Michael Lodberg Olsen
Oral presentation
4. How to run an unsanctioned overdose prevention van; experiences from Glasgow 2020-2021
15:00
to
16:30
Insights zone 3 (I3)
Peter H. Krykant
Oral presentation
The International Society of Substance Use Professionals (ISSUP)
15:00
to
16:30
Insights zone 2 (I2)
Joanna Travis-Roberts
Oral presentation
How does risk prevention (not) work? Learning from the realist, pragmatic, cluster-randomised trial of the RISKIT-CJS programme (with a null result)
15:00
to
16:30
Knowledge market 4 (K4)
Nadine Hendrie
Oral presentation
Anabolic androgenic steroid use population size estimation: a first stage study utilising a Delphi exercise
15:00
to
16:30
Knowledge market 4 (K4)
Vivian Hope
Oral presentation
Prevalence and socio-demographics correlates of cannabis vaping: Results from the 2018 & 2019 International Cannabis Policy Study
15:00
to
16:30
Knowledge market 4 (K4)
Gary Chan
Oral presentation
Systematic review and meta-analysis of the prevalence of prescription opioid dependence in patients with chronic non cancer pain (CNCP) treated with opioid painkillers
15:00
to
16:30
Knowledge market 4 (K4)
Kyla Thomas
Oral presentation
Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: the ETHOS Engage Study
15:00
to
16:30
Knowledge market 4 (K4)
Jason Grebely
Oral presentation
PLATO, an e-learning platform for European learners
15:00
to
16:30
Insights zone 2 (I2)
Marica Ferri
Oral presentation
European initiatives on training: a cumulative experience
15:00
to
16:30
Insights zone 2 (I2)
Rachele Donini
Oral presentation
UNODC- prevention quality standards
15:00
to
16:30
Insights zone 2 (I2)
Wadih Maalouf
Oral presentation
Association of opioid agonist treatment with mortality or rehospitalization following injection drug use-associated bacterial and fungal infections: linkage cohort study
15:00
to
16:30
Knowledge market 3 (K3)
Thomas Brothers
Oral presentation
0. Convergence in behavioural addictions: Introduction
15:00
to
16:30
Main stage
Zsolt Demetrovics
Oral presentation
3 Scenarios, 3 Alternative Addiction Futures for 2040
15:00
to
16:30
Central square 4 (C4)
Jessica Prendergast
Oral presentation
Does university education and training on addictions really represent new opportunity for increasing quality of workforce and addiction specific services in prevention, treatment and harm reduction?
15:00
to
16:30
Insights zone 2 (I2)
Michal Miovsky
16:50
Oral presentation
1. Analysis of NPS and drugs purchased on Darknet and Clearnet markets
16:50
to
18:20
Insights zone 4 (I4)
Mireia Ventura
Oral presentation
2. The influence of legislation on the availability of NPS
16:50
to
18:20
Insights zone 4 (I4)
Judith Aldridge
Oral presentation
3. Prevalence of NPS use. Results of the implementation of a standardized survey methodology amongst 25 civil society organization in Europe
16:50
to
18:20
Insights zone 4 (I4)
Jochen Schrooten
Oral presentation
1. The Impact of Economic Recessions on the Use of Illicit Drugs: a Systematic Review of Literature and a Meta-Analysis
16:50
to
18:20
Central square 4 (C4)
Claudia Costa Storti
Oral presentation
2. The impact of economic recessions on the harms of drug use and health responses, in Europe: a panel data analysis
16:50
to
18:20
Central square 4 (C4)
Bruno Casal
Oral presentation
3. Structural vulnerabilities and deaths of despair in Scotland, 1980-2021
16:50
to
18:20
Central square 4 (C4)
Mirjam Allik
Oral presentation
Integrating the Notions of Complexity and Social Suffering to Provide Better Care to Sexually and Gender-Diverse Men Who Use Methamphetamine
16:50
to
18:20
Insights zone 2 (I2)
Ida Giugnatico
Oral presentation
Sustaining non-use of party drugs among Dutch young adults
16:50
to
18:20
Insights zone 2 (I2)
Eefje Vercoulen
Oral presentation
Why do young people use cannabis – or decide not to?
16:50
to
18:20
Insights zone 2 (I2)
Anne Line Bretteville-Jensen
Oral presentation
LEt’s Talk about drugs: Assessment of drug education in Bulgaria, Hungary, Lithuania, Poland, and Serbia
16:50
to
18:20
Insights zone 2 (I2)
Maria Plotko
Oral presentation
Community involvement facilitating the discussion of alcohol use in primary care: A nominal group study
16:50
to
18:20
Central square 1 (C1)
Bram Pussig
Oral presentation
Modeling the Impact of a long-term horizon and multiple treatment episodes on the effectiveness and cost-effectiveness of alcohol treatment in the United States
16:50
to
18:20
Central square 1 (C1)
Carolina Barbosa
Oral presentation
Per capita alcohol consumption and alcohol-related harm: an analysis of long-term evidence from Nordic and Mediterranean countries
16:50
to
18:20
Central square 1 (C1)
Gregor Zwirn
Oral presentation
The modelled cost-effectiveness of two psychological treatments for the reduction of alcohol consumption in alcohol-dependent individuals
16:50
to
18:20
Central square 1 (C1)
Sergio Flores
Oral presentation
Can alcohol abstinence orders reduce mortality? Insights from an individual-level analysis of 24/7 Sobriety
16:50
to
18:20
Central square 1 (C1)
Beau Kilmer
Oral presentation
4. Illegal substance use during pregnancy: what do we know about risks and detoxification?
16:50
to
18:20
Central square 2 (C2)
Cleo L. Crunelle
Oral presentation
2. Impact and lessons learned in the implementation of a NBP model across the province of Quebec, Canada
16:50
to
18:20
Knowledge market 2 (K2)
Joël Tremblay
Oral presentation
1. Implementation of a substance use NBP model in a Northern Region of Ontario- results and lessons learned
16:50
to
18:20
Knowledge market 2 (K2)
Stephanie Paquette
Oral presentation
3. Development and pilot testing an integrated mental health and substance use Needs-based Planning model: Lessons learned for local planning and model refinements
16:50
to
18:20
Knowledge market 2 (K2)
Brian Rush
Oral presentation
1. First findings of an RCT on treatment of PTSD in addiction: simultaneous or sequential treatment with EMDR, Prolonged Exposure, Imaginary Rescripting
16:50
to
18:20
Central square 2 (C2)
Nathalie Faber
Oral presentation
5. Focus on implementation processes, impacts to date and pros and cons of the sustainability of the Australian Mental Health model
16:50
to
18:20
Knowledge market 2 (K2)
Sandra Diminic
Oral presentation
2. Older adults and alcohol use: negative affect, resilience, and alcohol use as interacting factors
16:50
to
18:20
Central square 2 (C2)
Yannick van Gils
Oral presentation
3. Effectiveness of a digital alcohol moderation intervention as an add-on to depression treatment for young adults: findings of a pragmatic randomized controlled trial
16:50
to
18:20
Central square 2 (C2)
Maria J.E. Schouten
Oral presentation
1. International Guidelines on Human Rights and Drug Policy: From standard setting to assessing compliance
16:50
to
18:20
Knowledge market 1 (K1)
Damon Barrett
Oral presentation
2. Pompidou Group for Human rights and drug policies in Europe: A self-assessment tool
16:50
to
18:20
Knowledge market 1 (K1)
Thomas Kattau
Oral presentation
3. The Global Drug Policy Index: A unique accountability tool to assess and rank countries’ drug policies
16:50
to
18:20
Knowledge market 1 (K1)
Juan Fernandez Ochoa
Oral presentation
1. The standard THC unit
16:50
to
18:20
Main stage
Tom Freeman
Oral presentation
2. Paving the Way for Improved Data Collection on Cannabis Use
16:50
to
18:20
Main stage
Susan Weiss
Oral presentation
3. The International Cannabis Toolkit (iCannToolkit): a first necessary step to integrate global multidisciplinary evidence on cannabis related risks and benefits
16:50
to
18:20
Main stage
Valentina Lorenzetti
Oral presentation
4. From standard drinks to the cannabis toolkit
16:50
to
18:20
Main stage
Antoni Gual
Oral presentation
1. Experimental studies on cannabis and driving impairment
16:50
to
18:20
Insights zone 3 (I3)
Tom Arkell
Oral presentation
2. Epidemiological studies on cannabis and crash risk
16:50
to
18:20
Insights zone 3 (I3)
Eef Theunissen
Oral presentation
3. Toxicology: detection of THC impairment
16:50
to
18:20
Insights zone 3 (I3)
Jan Ramaekers
Oral presentation
4. Policy and legislation
16:50
to
18:20
Insights zone 3 (I3)
Brendan Hughes
Oral presentation
An international rapid review of the needs and an indirect estimate of the national prevalence of women who use substances and endure domestic violence.
16:50
to
18:20
Central square 3 (C3)
Catherine Comiskey
Oral presentation
5. Medical use and novel cannabinoids
16:50
to
18:20
Insights zone 3 (I3)
Robyn Robertson
Oral presentation
What are the attitudes of pregnant women and mothers concerning maternal alcohol use, and what factors are associated with increased maternal drinking?
16:50
to
18:20
Central square 3 (C3)
Abi Rose
Oral presentation
Identifying the needs of mothers in substance use treatment services using electronic health records
16:50
to
18:20
Central square 3 (C3)
Martha Canfield
Oral presentation
Metzineres. Environments of Shelter for Womxn who use drugs surviving violence
16:50
to
18:20
Central square 3 (C3)
Aura Roig Forteza
Oral presentation
Prevalence of Tobacco Smoking in Austria. Differences between Women and Men
16:50
to
18:20
Central square 3 (C3)
Irene Schmutterer
Oral presentation
1. The role of social work in agency processes - empirical study using the example of people who use illicit substances with a history of imprisonment
16:50
to
18:20
Networking zone 1 (N1)
Daniela Jamin
Oral presentation
2. Social work with drug users in a probation system of Kyrgyzstan
16:50
to
18:20
Networking zone 1 (N1)
Estebes uulu Tynchtyk
Oral presentation
3. Health and social welfare in prisons in the Republic of Kazakhstan – women with HIV and the role of the social worker
16:50
to
18:20
Networking zone 1 (N1)
Dalida Mukasheva
Oral presentation
Drug treatment facilities survey, Tunisia 2020
16:50
to
18:20
Networking zone 2 (N2)
Hajer Aounallah-Skhiri
Oral presentation
Findings from treatment facility survey (EFSQ) in Lebanon’
16:50
to
18:20
Networking zone 2 (N2)
Zeinab Abbas
Oral presentation
European facility survey questioner (EFSQ) for Palestinian substance use disorder (SUD) treatment facilities.
16:50
to
18:20
Networking zone 2 (N2)
Saed Bilbeisi
Oral presentation
European treatment facility survey in Georgia
16:50
to
18:20
Networking zone 2 (N2)
Irakli Natsvlishvili
Oral presentation
1. Interventions to enhance prevention of hepatitis C and HIV infection
16:50
to
18:20
Knowledge market 3 (K3)
Julie Bruneau
Oral presentation
2. Treatment as prevention for hepatitis C infection: A key piece to the elimination puzzle
16:50
to
18:20
Knowledge market 3 (K3)
Matthew Hickman
Oral presentation
3. We have reached single-diagnosis and treatment for hepatitis C infection: What next?
16:50
to
18:20
Knowledge market 3 (K3)
Jason Grebely
Oral presentation
4. Community-led initiatives to enhance prevention and treatment for hepatitis C
16:50
to
18:20
Knowledge market 3 (K3)
Judy Chang
Thursday, 24 November
09:00
Oral presentation
2. Addiction Curriculum in Nigerian Higher Education System – Contextualizing Western-based methods and approaches for responsiveness and effectiveness.
09:00
to
10:30
Central square 4 (C4)
Martin Agwogie
Oral presentation
3. Piloting an implementation protocol delivered as an online course: African leadership in addiction workforce development
09:00
to
10:30
Central square 4 (C4)
Beatrice Kathungu
Oral presentation
1. Needs Assessment of Addiction Science Programmes at Universities in South Africa and Preparatory work for curriculum development
09:00
to
10:30
Central square 4 (C4)
Rehana Kader
Oral presentation
2. New challenges in drug monitoring: wastewater analysis as an alternative indicators for rapid epidemiological assessment of drug use trend
09:00
to
10:30
Knowledge market 4 (K4)
José Benito Quintana
Oral presentation
3. Promotion of health regarding the problematic drug use through interventions in educational and primary addiction treatment settings
09:00
to
10:30
Knowledge market 4 (K4)
Victor Villanueva
Oral presentation
4. Translational research as a necessary actor for fighting addiction: RIAPAd as a coordinated national cooperative framework
09:00
to
10:30
Knowledge market 4 (K4)
Fernando Rodriguez De Fonseca
Oral presentation
1. Implementing patient-reported experiences (PROMs and PREMs) to improve the engagement of patients in treatment services
09:00
to
10:30
Knowledge market 4 (K4)
Joan-Ignasi Mestre-Pintó
Oral presentation
ROSE: A peer-led intervention to support peer workers in overdose response settings in British Columbia
09:00
to
10:30
Central square 2 (C2)
Fred Cameron
Oral presentation
Stakeholders’ perceptions about their position and the dynamics between the stakeholders within Swedish drug policy field
09:00
to
10:30
Central square 2 (C2)
Tuulia Lerkkanen
Oral presentation
Switching from a criminalisation to a public health approach to injecting drug use in Eastern Europe and Central Asia: a modelling analysis of the costs and impact on HIV transmission
09:00
to
10:30
Central square 2 (C2)
Zoe Ward
Oral presentation
Addressing intimate partner abuse (IPA) perpetrated by heterosexual men in substance use treatment: the ADVANCE programme
09:00
to
10:30
Central square 2 (C2)
Gail Gilchrist
10:50
Oral presentation
2. HTP prevalence in England and use for smoking cessation
10:50
to
12:20
Insights zone 4 (I4)
Harry Tattan-Birch
Oral presentation
3. Perceived health risks of heated tobacco products, tobacco cigarettes, and e-cigarettes: Findings from a populationbased cross-sectional household survey in Germany (DEBRA study)
10:50
to
12:20
Insights zone 4 (I4)
Stephanie Klosterhalfen
Oral presentation
4. Harm perceptions of heated tobacco products and vaping among students at Lithuanian universities
10:50
to
12:20
Insights zone 4 (I4)
Erikas Simonavičius
Oral presentation
5. It’s not what you’d term normal smoking’: A qualitative exploration of HTP user identity
10:50
to
12:20
Insights zone 4 (I4)
Katherine A. East
Oral presentation
1. Global Prevalence of Heated Tobacco Product Use: A Systematic Review and Meta-analysis
10:50
to
12:20
Insights zone 4 (I4)
Tianze Sun
Oral presentation
Non-drinking as deviant! First attempts to use the Relational Responding Task to alter drinking identity in an experimental study.
10:50
to
12:20
Insights zone 2 (I2)
Helle Larsen
Oral presentation
The Power of Social Networks: Trial Outcomes of a Two-Stage Social Network Intervention Aimed at Reducing Hazardous Drinking in the First Twelve Months at Residential College.
10:50
to
12:20
Insights zone 2 (I2)
Lily Davidson
Oral presentation
The association between social media use and substance use behaviour among adolescents: The ABCD-Study
10:50
to
12:20
Insights zone 2 (I2)
Hanan Bozhar
Oral presentation
Quem conta um conto acrescenta um ponto': Drugs as news in Portugal
10:50
to
12:20
Insights zone 2 (I2)
Pedro Barbosa
Oral presentation
Implementing a Moderate Alcohol Use Program for Indigenous People: A Stakeholder Perspective
10:50
to
12:20
Central square 1 (C1)
Pascale Alarie-vézina
Oral presentation
Simulation of Alcohol Control Policies for Health Equity (SIMAH): Study design and first results
10:50
to
12:20
Central square 1 (C1)
Charlotte Probst,
Robin Purshouse
Oral presentation
Noticed and then forgotten: gender in alcohol policy stakeholder responses to alcohol and violence
10:50
to
12:20
Central square 1 (C1)
David Moore
Oral presentation
Impact of introducing a minimum alcohol tax share in retail prices on alcohol-attributable mortality in the WHO European Region: a modelling study
10:50
to
12:20
Central square 1 (C1)
Pol Rovira Escarrà
Oral presentation
The association between moral injury and cannabis use disorder among Israeli combat veterans: current state of knowledge and future directions
10:50
to
12:20
Knowledge market 2 (K2)
Daniel Feingold
Oral presentation
Alcohol and drug use among trauma patients with injuries of violence– results from the IDART study
10:50
to
12:20
Knowledge market 2 (K2)
Benedicte Jørgenrud
Oral presentation
addictive disorders and post-traumatic stress disorders
10:50
to
12:20
Knowledge market 2 (K2)
Léa Montagnier
Oral presentation
A novel trauma-focused psychological therapy for co-occurring substance use and PTSD among adolescents
10:50
to
12:20
Knowledge market 2 (K2)
Emma Barrett
Oral presentation
Experienced gratification and compensation in addictive behaviors: Investigating its relevance in different types of Internet-use disorders
10:50
to
12:20
Insights zone 3 (I3)
Stephanie Antons
Oral presentation
Understanding first controlled gaming in teenagers. A qualitative study among young French daily or week-end gamers
10:50
to
12:20
Insights zone 3 (I3)
Carine Mutatayi
Oral presentation
Assessment of Criteria for Specific Internet-use Disorders (ACSID-11):Further development and validation of a new screening instrument capturing ICD-11 criteria for gaming disorder and other potential Internet-use disorders
10:50
to
12:20
Insights zone 3 (I3)
Andreas Oelker
Oral presentation
Problematic gaming risk among European adolescents: A cross-national evaluation of individual and socio-economic factors
10:50
to
12:20
Insights zone 3 (I3)
Sabrina Molinaro
Oral presentation
Effects of COVID-19 lockdowns on addiction to social networking sites and associations with changes in loneliness, sexual functioning, and eating styles
10:50
to
12:20
Insights zone 3 (I3)
Rui Costa
Oral presentation
1. The International Cannabis Policy Study – Framework for evaluating cannabis legalization
10:50
to
12:20
Knowledge market 1 (K1)
David Hammond
Oral presentation
2. Patterns of problematic cannabis use among Canadian and US respondents between 2018 and 2020: Findings from the International Cannabis Policy Study
10:50
to
12:20
Knowledge market 1 (K1)
Cesar Leos-Toro
Oral presentation
3. Perceptions of illegal and legal cannabis in Canada in the three years after cannabis legalization: Findings from the International Cannabis Policy Study
10:50
to
12:20
Knowledge market 1 (K1)
TBD TBD
Oral presentation
Practitioner perspectives on working with older patients in opioid agonist treatment (OAT) in Norway
10:50
to
12:20
Knowledge market 3 (K3)
John Todd-kvam
Oral presentation
Integrating harm reduction in homelessness services. The HR4H Key Principles
10:50
to
12:20
Knowledge market 3 (K3)
Roberto Perez Gayo
Oral presentation
1. Synthetic opioids in Sweden: Analyses of public webforum discussions
10:50
to
12:20
Central square 2 (C2)
Kim Moeller
Oral presentation
2. From the jungle to the street: Country-level variation and demographic correlates of cocaine prices
10:50
to
12:20
Central square 2 (C2)
Rasmus Munksgaard
Oral presentation
3. Illegal drug markets on social media: Locally bound actors on global platforms
10:50
to
12:20
Central square 2 (C2)
Silje Anderdal Bakken
Oral presentation
4. How do you become involved in hybrid digital drug markets: Identifying explanations in a qualitative interview study with social media sellers
10:50
to
12:20
Central square 2 (C2)
Jakob Demant
Oral presentation
Mental health and associations with tobacco smoking and quitting behaviour in the population of Germany
10:50
to
12:20
Central square 3 (C3)
Sabrina Kastaun
Oral presentation
Neuropsychology of Addictions in Therapeutic Communities: assessing and understanding cognitive recovery through a residential treatment of substance use disorders
10:50
to
12:20
Central square 3 (C3)
Simon Deniel
Oral presentation
Administration matters! A retrospective cohort study of medication dispensing at pharmacies
10:50
to
12:20
Knowledge market 3 (K3)
Birgitte Thylstrup
Oral presentation
Binge alcohol intake triggers microglial activation and TNF-dependent aberrant synaptic pruning, causing synapse loss and increased anxiety
10:50
to
12:20
Central square 3 (C3)
Teresa Summavielle
Oral presentation
Primary Care Provider expectations of addiction services and patients in Spain.
10:50
to
12:20
Knowledge market 3 (K3)
Pablo Barrio
Oral presentation
High dose anabolic steroid use and facial emotion recognition, the hormonal influence on social cognition.
10:50
to
12:20
Central square 3 (C3)
Astrid Bjørnebekk
Oral presentation
Optimising take home naloxone intervention delivery in the community (retail) pharmacy setting.
10:50
to
12:20
Knowledge market 3 (K3)
Jennifer Scott
Oral presentation
2. Streetwork and Outreach Networking
10:50
to
12:20
Knowledge market 4 (K4)
Lagakou Litsa
Oral presentation
3. Direct access to OST treatment and integrated therapy: Lessons learned from streets to community
10:50
to
12:20
Knowledge market 4 (K4)
Nikos Avgerinos
Oral presentation
4. Harm Reduction and Covid 19: Hostel 'IONIS', an example of a holistic intervention for homeless drug users
10:50
to
12:20
Knowledge market 4 (K4)
Foteini Leobilla
Oral presentation
1. The 4 pillar drug policy and city overview
10:50
to
12:20
Central square 4 (C4)
Andrea Weiss
Oral presentation
3. t-alk' and 'City' – low-threshold meeting places for a diverse clientele
10:50
to
12:20
Central square 4 (C4)
Larissa Stämpfli
Oral presentation
2. Surpervised drug consumption facilities (SDCF)
10:50
to
12:20
Central square 4 (C4)
Janine Lanz
Oral presentation
4. sip züri' - entry control of safe injection facilities, and from social space management to social ambulance
10:50
to
12:20
Central square 4 (C4)
Mara Brügger
Oral presentation
5. Flora Dora' and prostitution area team: outreach social work for sexworkers and low-threshold counselling on the spot
10:50
to
12:20
Central square 4 (C4)
Ursula Kocher
Oral presentation
1. Steps forward in an attempt of OKANA to widen harm reduction to risk reduction: entries and facilities within a new concept based on the real needs
10:50
to
12:20
Knowledge market 4 (K4)
Athanasios Theocharis
Oral presentation
1. Representations of narcoculture
10:50
to
12:20
Insights zone 1 (I1)
América Tonantzin Becerra Romero
Oral presentation
2. Journalism and illegal drugs, a complex relationship
10:50
to
12:20
Insights zone 1 (I1)
Daniel Font Noguerol
Oral presentation
3. Harm reduction and addiction in social media. How to do it right?
10:50
to
12:20
Insights zone 1 (I1)
Damian Sobczyk
Oral presentation
4. ACEs to Assets
10:50
to
12:20
Insights zone 1 (I1)
Dave Higham
12:20
Oral presentation
Health and social effects of non-medical cannabis use: an update
12:20
to
12:40
Insights zone 4 (I4)
Eva Hoch
12:40
Oral presentation
What is new in the WHO Consolidated Guidelines for HIV, viral hepatitis and STI prevention, diagnosis and treatment for key populations
12:40
to
12:50
Insights zone 4 (I4)
Annette Verster
12:50
Oral presentation
Global monitoring of progress with attainment of SDG health target 3.5 and service capacity for substance use disorders
12:50
to
13:05
Insights zone 4 (I4)
Vladimir Poznyak
13:20
Oral presentation
Codesigning an Australian National Prompt Response Network for Emerging Drugs
13:20
to
14:50
Insights zone 4 (I4)
Penelope Hill
Oral presentation
A qualitative study of people who use new psychoactive substances and harm reduction services in eight countries of Eastern Europe and Central Asia region
13:20
to
14:50
Insights zone 4 (I4)
Eliza Kurcevič
Oral presentation
In vitro pharmacological characterization of recent non-fentanyl synthetic opioids including 2-benzylbenzimidazole ‘nitazene’ opioids
13:20
to
14:50
Insights zone 4 (I4)
Marthe Vandeputte
Oral presentation
Cannabis adulterated with the synthetic cannabinoid receptor agonist MDMB-4en-PINACA and the role of European drug checking services
13:20
to
14:50
Insights zone 4 (I4)
Pieter E. Oomen
Oral presentation
3. Municipalities in the lead: an approach to tackle GHB-related problems in the Netherlands.
13:20
to
14:50
Insights zone 2 (I2)
Anneke Van Wamel
Oral presentation
1. Development and implementation of an environmental prevention intervention at local level
13:20
to
14:50
Insights zone 2 (I2)
Ina Koning
Oral presentation
2. Choosing our theories wisely: the importance of theory for effective and ethical environmental prevention
13:20
to
14:50
Insights zone 2 (I2)
Angelina Brotherhood
Oral presentation
Drinking with Coworkers – How to Make it a Safe and Including Event
13:20
to
14:50
Central square 1 (C1)
Stian Fjerdingen
Oral presentation
Accuracy, acceptability, and feasibility of transdermal alcohol sensors: Two systematic reviews
13:20
to
14:50
Central square 1 (C1)
Eileen Brobbin
Oral presentation
Perceived barriers and facilitators to accessing effective clinical supervision and the implementation of a clinical supervision exchange model in the alcohol and other drug sector
13:20
to
14:50
Central square 1 (C1)
Courtney O'Donnell
Oral presentation
Using technology to digitally disrupt the delivery of outcome measures in Alcohol and Other Drug (AOD) services
13:20
to
14:50
Central square 1 (C1)
Leanne Hides
Oral presentation
The Role of Adverse Childhood Experiences (ACEs) on People in Opiate Agonist Treatment: The importance of feeling unloved
13:20
to
14:50
Knowledge market 2 (K2)
David McDonagh
Oral presentation
Longitudinal patterns of problematic cannabis use in adolescence and their association with childhood psychological risk factors
13:20
to
14:50
Knowledge market 2 (K2)
Rachel Lees
Oral presentation
Childhood maltreatment and alcohol problems in young adulthood: coping style as a mediator and potential intervention target.
13:20
to
14:50
Knowledge market 2 (K2)
Lucinda Grummitt
Oral presentation
Exploring the link between childhood maltreatment and substance use disorder using a prospective, genetically informative and experimental approach
13:20
to
14:50
Knowledge market 2 (K2)
Andrea Johansson Capusan
Oral presentation
Declining Prevalence of Current HCV Infection and Increased Treatment Uptake Among People Who Inject Drugs: The ETHOS Engage Study
13:20
to
14:50
Knowledge market 3 (K3)
Anna Conway
Oral presentation
Non-uptake of treatment for hepatitis C in the antiviral era: A qualitative analysis
13:20
to
14:50
Knowledge market 3 (K3)
Suzanne Fraser
Oral presentation
A novel hepatitis C intervention in Denmark to test and treat people who inject drugs
13:20
to
14:50
Knowledge market 3 (K3)
Jonas Demant
Oral presentation
Gambling addiction, gambling related harm and gambling problems - a knowledge synthesis and research agenda
13:20
to
14:50
Insights zone 3 (I3)
Antonius Van Rooij
Oral presentation
Competing framings of gambling as a distinct vs similar problem – boundary making with substance use and eating disorders.
13:20
to
14:50
Insights zone 3 (I3)
Eva Samuelsson
Oral presentation
Putting together the puzzle of gambling addiction
13:20
to
14:50
Insights zone 3 (I3)
Martin Busch
Oral presentation
1. Cannabis Social Clubs in Europe: a transnational social movement network in the making?
13:20
to
14:50
Knowledge market 4 (K4)
Melissa Bone
Oral presentation
3. Legal or not: a comparative analysis of Belgian and Uruguayan CSC members’ profile and policy preferences
13:20
to
14:50
Knowledge market 4 (K4)
Lorena Repetto
Oral presentation
4. Drug social clubs – the next social club generation?
13:20
to
14:50
Knowledge market 4 (K4)
Chris Wilkins
Oral presentation
2. Estimating the prevalence of opioid dependence in New South Wales from multiple data sources: case study application of a Bayesian modelling approach
13:20
to
14:50
Central square 2 (C2)
Hayley E. Jones
Oral presentation
3. Estimates of people who injected drugs within the past 12 months in France
13:20
to
14:50
Central square 2 (C2)
Eric Janssen
Oral presentation
4. How many people injected illicit drugs in the European Union in 2019?
13:20
to
14:50
Central square 2 (C2)
Filippo Pericoli
Oral presentation
1. Estimates of people who injected drugs within the last 12 months in Belgium
13:20
to
14:50
Central square 2 (C2)
Luk Van Baelen
Oral presentation
5. Updated global estimates of prevalence of People Who Inject Drugs and coverage of harm reduction – what has changed between 2017 and 2021
13:20
to
14:50
Central square 2 (C2)
Samantha Colledge-Frisby
Oral presentation
What will the future nicotine market look like in a post-smoking era?
13:20
to
14:50
Central square 3 (C3)
Karl Erik Lund
Oral presentation
Effectiveness of e-cigarettes for smoking cessation in the German population - a comparison with nicotine replacement therapy and no use of evidence-based support (DEBRA study)
13:20
to
14:50
Central square 3 (C3)
Daniel Kotz
Oral presentation
The lifetime costs and benefits of subsidizing the cost of nicotine replacement therapy in Sweden
13:20
to
14:50
Central square 3 (C3)
Inna Feldman
Oral presentation
Cessation of Smoking Trial in the Emergency Department- interim results
13:20
to
14:50
Central square 3 (C3)
Ian Pope
Oral presentation
Motivation to stop smoking in the German population: recent trends and associated factors (DEBRA study)
13:20
to
14:50
Central square 3 (C3)
Benjamin Borchardt
Oral presentation
1. Association of cannabis and tobacco use with incident anxiety, mood and psychotic disorders: a systematic review
13:20
to
14:50
Knowledge market 1 (K1)
Chloe Burke
Oral presentation
3. The Cannabis And Tobacco Cessation Advice (CATCA) project: A mixed method study exploring UK stop smoking practitioners’ knowledge, attitudes and practices around co-use
13:20
to
14:50
Knowledge market 1 (K1)
Maria Duaso
Oral presentation
4. Changes in tobacco use among people with cannabis use disorder treated in programs
13:20
to
14:50
Knowledge market 1 (K1)
Cristina Martínez
Oral presentation
2. Quitting experiences, attitudes and beliefs amongst UK young adult co-smokers: A qualitative interview study
13:20
to
14:50
Knowledge market 1 (K1)
Hannah Walsh
Oral presentation
4. A qualitative exploration of three hypothetical models of drug checking service delivery in a Scottish context
13:20
to
14:50
Central square 4 (C4)
Danilo Falzon
Oral presentation
The added value of drug checking data in combination with data from online drug monitoring to evaluate NPS market dynamics: the case of 3-MMC in the Netherlands.
13:20
to
14:50
Insights zone 4 (I4)
Laura Smit-rigter
Oral presentation
1. Implementing community-based drug checking services in two Canadian provinces: lessons learned and ways forward
13:20
to
14:50
Central square 4 (C4)
Karen McDonald
Oral presentation
2. Tailoring drug checking services to Drug Consumption Rooms
13:20
to
14:50
Central square 4 (C4)
Mireia Ventura
Oral presentation
3. Drug checking in DCRs in Switzerland: a new harm reduction tool?
13:20
to
14:50
Central square 4 (C4)
Florian Meyer,
Pierre Esseiva
Oral presentation
1. How Robust and Innovative are Illegal Drug Markets?
13:20
to
14:50
Main stage
Peter H. Reuter
Oral presentation
2. To what extent can drug violence indicators tell us something about underlying drug market activity?
13:20
to
14:50
Main stage
Marieke Liem
Oral presentation
2. What are the barriers and prospects for establishing Cannabis Social Clubs in New Zealand?
13:20
to
14:50
Knowledge market 4 (K4)
Marta Rychert
Oral presentation
4. The geography of drug markets and hotspots of violence
13:20
to
14:50
Main stage
Tuesday Reitano
15:00
Oral presentation
5. Modeling safer supply programs: a qualitative evaluation of three safer opioid supply program models in British Columbia, Canada
15:00
to
16:30
Insights zone 4 (I4)
Andrew Ivsins,
Geoff Bardwell
Oral presentation
2. Implementation of safe supply alternatives during intersecting COVID-19 and overdose health emergencies in British Columbia, Canada, 2021
15:00
to
16:30
Insights zone 4 (I4)
Allison Barker
Oral presentation
1. Why people who use drugs need a safe regulated supply of all drugs
15:00
to
16:30
Insights zone 4 (I4)
Natasha Touesnard,
Matthew Alexander Bonn
Oral presentation
3. A mixed methods evaluation of risk mitigation measures to address the dual public health crisis of COVID-19 and overdose
15:00
to
16:30
Insights zone 4 (I4)
Karen Urbanoski,
Bernie Pauly
Oral presentation
Quality management in prevention of risk behaviors in school setting: a Case study from Czech republic
15:00
to
16:30
Insights zone 2 (I2)
Elizabeth Novakova
Oral presentation
4. A sea of need – Safe opioid supply service provider accounts of implementing admission priorities
15:00
to
16:30
Insights zone 4 (I4)
Carol Strike
Oral presentation
The 7-year effectiveness of school-based alcohol use prevention from adolescence to early adulthood: An RCT of universal, selective and combined interventions.
15:00
to
16:30
Insights zone 2 (I2)
Nicola Newton
Oral presentation
Design and Evaluation of a neuroscience-based, harm reduction program to prevent alcohol and illicit substance use among late adolescents: An RCT of the Illicit Project
15:00
to
16:30
Insights zone 2 (I2)
Emily Stockings
Oral presentation
Durability of anxiety, depression, and substance use prevention effects from teenage years to young adulthood: 6-year outcomes from a school-based cluster randomised controlled trial delivered in adolescence.
15:00
to
16:30
Insights zone 2 (I2)
Zachary Bryant
Oral presentation
2. Lessons for the future of alcohol surveys
15:00
to
16:30
Central square 1 (C1)
Jürgen Rehm
Oral presentation
1. Developing and Extending Evidence and Practice from the Standard European Alcohol Survey (DEEP SEAS): Key findings, strengths, and limitations
15:00
to
16:30
Central square 1 (C1)
Carolin Kilian
Oral presentation
The role of place-making dynamics in recovery from co-occurring disorders: An in-depth ethnographic study
15:00
to
16:30
Knowledge market 2 (K2)
Clara De Ruysscher
Oral presentation
The social, material and temporal effects of extended-release buprenorphine depot treatment for opioid dependence: an Australian qualitative study
15:00
to
16:30
Knowledge market 3 (K3)
Kari Lancaster
Oral presentation
Changes in mental health among drug users during Covid-19. Evidence from a repeated cross-sectional survey in Belgium
15:00
to
16:30
Knowledge market 2 (K2)
Elena Damian
Oral presentation
Online peer support for concurring mental health and addiction problems during the Covid19 pandemic: feeling of group inclusion and perceived effectiveness.
15:00
to
16:30
Knowledge market 2 (K2)
Raffaella Milani
Oral presentation
2. Where does the gambling surplus come from? Outline of a theory of asymmetric market
15:00
to
16:30
Insights zone 3 (I3)
Pekka Sulkunen
Oral presentation
3. The framing of commercial determinants of harm: challenges for regulation in the UK
15:00
to
16:30
Insights zone 3 (I3)
Heather Wardle,
Gerda Reith
Oral presentation
4. Meta-analysis of self-regulation discourses
15:00
to
16:30
Insights zone 3 (I3)
Gerda Reith
Oral presentation
5. Ways gambling industry pursues influence with policymakers
15:00
to
16:30
Insights zone 3 (I3)
Peter J. Adams
Oral presentation
1. State-owned gambling in global competitive environment
15:00
to
16:30
Insights zone 3 (I3)
Johanna Järvinen-Tassopoulos
Oral presentation
Serious non-fatal and fatal opioid overdose events in a cohort of hospital patients seen by an addiction consultation service: Secondary analysis of the NavSTAR trial.
15:00
to
16:30
Knowledge market 3 (K3)
Jan Gryczynski
Oral presentation
Screening, diagnosis and treatment of infectious diseases with at-risk populations: 20 years of data from a harm reduction program managed by Ares do Pinhal in Lisbon
15:00
to
16:30
Knowledge market 3 (K3)
Filipa Barata
Oral presentation
Peer-led community based infectious disease integrated testing and linkage to care in inclusion health populations in London, UK
15:00
to
16:30
Knowledge market 3 (K3)
Julian Surey
Oral presentation
2. Drug-related deaths in prisons in England and Wales, 2015-2020: an examination of key trends and issues for policy and practice
15:00
to
16:30
Knowledge market 1 (K1)
Karen Duke
Oral presentation
3. The role of Primary Care in the prevention of drug-related deaths: Patient and family member perspectives
15:00
to
16:30
Knowledge market 1 (K1)
Katie Colliver
Oral presentation
4. The role of Primary Care in the prevention of drug-related deaths: service provider perspectives
15:00
to
16:30
Knowledge market 1 (K1)
Betsy Thom
Oral presentation
5. Drug Policy and The Rise and Decline of Racial Stratification of Prescribing and Overdose Mortality
15:00
to
16:30
Knowledge market 1 (K1)
Brian Kelly
Oral presentation
1. Drug-related deaths among young people: a social, structural and systems autopsy
15:00
to
16:30
Knowledge market 1 (K1)
Aileen O'Gorman
Oral presentation
2. Improving the self: Psychedelic drug use and the enhancement-treatment debate
15:00
to
16:30
Main stage
Margit Anne Petersen
Oral presentation
3. Psychedelics in psychiatry: focus on evidence and mechanisms of relevance to affective disorders and addictions
15:00
to
16:30
Main stage
David Erritzoe
Oral presentation
1. Combining Psychedelic Treatments with Current Substance Use Disorder Treatments
15:00
to
16:30
Main stage
Johannes Thrul
Oral presentation
2. The clinical impact of ethanol co-use in patients with acute drug toxicity involving the use of central nervous system depressant recreational drugs
15:00
to
16:30
Central square 2 (C2)
Eva-Carina Heier
Oral presentation
3. Variation in the drugs involved in acute drug toxicity presentations based on age and sex within the Euro-DEN Plus dataset
15:00
to
16:30
Central square 2 (C2)
Òscar Miró
Oral presentation
4. Deaths among acute drug toxicity presentations to the Euro-DEN Plus Network, 2014-2020
15:00
to
16:30
Central square 2 (C2)
Isabelle Giraudon
Oral presentation
Who is using take-home naloxone? An examination of super-savers
15:00
to
16:30
Central square 3 (C3)
Desiree Eide
Oral presentation
Examining health care from the drug user perspective: what works, what doesn't and what needs to change
15:00
to
16:30
Central square 3 (C3)
Mary Ellen Harrod
Oral presentation
An Evaluation of the Co-Design of an Anti-Stigma Training Programme
15:00
to
16:30
Central square 3 (C3)
Sonam Prakashini Banka
Oral presentation
Once you’ve addressed your drinking, we’ll address your mental health': A qualitative exploration of patient and providers’ experiences of services for co-occurring heavy drinking and depression in North East England
15:00
to
16:30
Central square 3 (C3)
Amy O'Donnell
Oral presentation
Police officers’ attitudes and practices toward harm reduction services in Sweden – a qualitative study
15:00
to
16:30
Central square 3 (C3)
Johan Nordgren
Oral presentation
1. New Psychoactive Substance Presentations to the Euro-DEN Plus Network
15:00
to
16:30
Central square 2 (C2)
Benjamin Crulli
Oral presentation
3. Development of tailored prevention intervention packages
15:00
to
16:30
Knowledge market 4 (K4)
Magdalena Rowicka
Oral presentation
1. Aims, scope and methodology of IMPRESA
15:00
to
16:30
Knowledge market 4 (K4)
Dovilė Mačiulytė
Oral presentation
2. Results of the literature review and the Delphi expert consensus finding process on Methamphetamine Prevention Interventions
15:00
to
16:30
Knowledge market 4 (K4)
Benjamin Petruželka
Oral presentation
4. The RE-AIM framework for evaluating implementation processes and public health impact
15:00
to
16:30
Knowledge market 4 (K4)
Harald Lahusen
Oral presentation
3. Are there good alternatives or add ons to surveys?
15:00
to
16:30
Central square 1 (C1)
Pia Mäkelä
Oral presentation
0. Insights into acute recreational drug and NPS toxicity: an update from the Euro DEN Plus Project: Introduction
15:00
to
16:30
Central square 2 (C2)
Paul Dargan
16:50
Oral presentation
1. Drug Market and Use Changes During the COVID-19 Pandemic: A Global Survey
16:50
to
18:20
Insights zone 4 (I4)
Alexander Baldacchino
Oral presentation
2. Cognitive Training and Rehabilitation Approaches for Addiction: A Delphi Consensus
16:50
to
18:20
Insights zone 4 (I4)
Hamed Ekhtiari
Oral presentation
3. A Methodological Checklist for fMRI Cue Reactivity Studies in Addictions: Development and Expert Consensus
16:50
to
18:20
Insights zone 4 (I4)
Antonio Verdejo-Garcia
Oral presentation
4. Translating Neuroscience into Addiction Prevention: A Delphi Consensus Study
16:50
to
18:20
Insights zone 4 (I4)
Tara Rezapour
Oral presentation
5. Global Experts-centered Consensus Development; A Series of Methodologies for Extending Harmonization and Global Representativeness in Addiction Science
16:50
to
18:20
Insights zone 4 (I4)
Arash Khojasteh Zonoozi
Oral presentation
The acceptability and feasibility of implementing and evaluating the Parents under Pressure (PuP) parenting programme with opioid-dependent fathers and their families: results from the PuP4Dads study.
16:50
to
18:20
Central square 3 (C3)
Anne Whittaker
Oral presentation
1. A predictive processing account of problem gambling
16:50
to
18:20
Insights zone 3 (I3)
Jarno Tuominen
Oral presentation
2. Flow in (problem) gambling
16:50
to
18:20
Insights zone 3 (I3)
Valtteri Arstila
Oral presentation
3. The ethical implications of how problem gambling is conceptualized
16:50
to
18:20
Insights zone 3 (I3)
Susanne Uusitalo
Oral presentation
The limitations of decriminalization at overdose events and lessons from an evaluation in British Columbia, Canada
16:50
to
18:20
Knowledge market 1 (K1)
Alissa Greer
Oral presentation
Medical cannabis regulation: Taking the best of the North American and European models
16:50
to
18:20
Insights zone 2 (I2)
Davide Fortin
Oral presentation
The change in methadone dispensing requirements in England during the first wave of the COVID-19 pandemic was associated with an increase in deaths from non-prescribed methadone
16:50
to
18:20
Knowledge market 1 (K1)
Caroline Copeland
Oral presentation
Municipal variations in cannabis regulation regarding public consumption and retail sales in Canada
16:50
to
18:20
Insights zone 2 (I2)
Christophe Huynh
Oral presentation
Differences in cannabis use and opinions on drug policy between generations
16:50
to
18:20
Central square 2 (C2)
Pekka Hakkarainen
Oral presentation
Long term public health benefits and cost-effectiveness of two experimental drug consumption rooms in France
16:50
to
18:20
Knowledge market 1 (K1)
Perrine Roux
Oral presentation
Québec's public, not-for-profit cannabis distribution regime: a comparative analysis, three years in
16:50
to
18:20
Insights zone 2 (I2)
François Gagnon
Oral presentation
Adolescent cannabis use during a period of rapid policy change: Evidence from the US PATH Study
16:50
to
18:20
Central square 2 (C2)
Mike Vuolo
Oral presentation
The United Kingdom’s first unsanctioned safe injecting facility; a proof-of-concept evaluation
16:50
to
18:20
Knowledge market 1 (K1)
Gillian Shorter
Oral presentation
Regulating Cannabis for Public Health
16:50
to
18:20
Insights zone 2 (I2)
Seema Pessar
Oral presentation
The role played by evidence on the effects of cannabis use in cannabis policy 1992-2022
16:50
to
18:20
Central square 2 (C2)
Eva Hoch
Oral presentation
First low-threshold gender responsive residential resource for homeless people using drugs in Barcelona: descriptive evaluation of the first 6 months of activity.
16:50
to
18:20
Knowledge market 1 (K1)
Gabriela Barbaglia
Oral presentation
Mitigating the risks of corporate capture in emerging legal cannabis markets
16:50
to
18:20
Insights zone 2 (I2)
Stephen Rolles
Oral presentation
Trajectories of Prescribed Medical Cannabis Filled Over Time
16:50
to
18:20
Central square 2 (C2)
Alexandra Kritikos
Oral presentation
Equity in Marijuana Policies: A Comparative Study of two U.S. States using Critical Race Theory.
16:50
to
18:20
Insights zone 2 (I2)
Gaby Mohr
Oral presentation
Suicide and self-harm during COVID-19 and beyond.
16:50
to
18:20
Main stage
Navneet Kapur
Oral presentation
Adolescent substance use, self-harm and suicide: Findings from the Northern Finland Birth Cohort 1986.
16:50
to
18:20
Main stage
Solja Niemelä
Oral presentation
Restricting access to means: Public health approaches to reduce drug- and alcohol-related self-harm.
16:50
to
18:20
Main stage
Eve Griffin
Oral presentation
3. Brain reward function in young people with a dsm-5 diagnosis of Cannabis Use Disorder: a fMRI study
16:50
to
18:20
Knowledge market 2 (K2)
Valentina Lorenzetti
Oral presentation
1. Cannabis use disorder and the brain: What’s culture got to do with it?
16:50
to
18:20
Knowledge market 2 (K2)
Janna Cousijn
Oral presentation
2. Resting state functional connectivity of the dorsal attention network in cannabis use disorder: a fMRI study
16:50
to
18:20
Knowledge market 2 (K2)
Lisa-Marie Greenwood
Oral presentation
Identification of cannabis user profiles and their engagement with polydrug use among respondents of the European Web Survey on Drugs: findings from Luxembourg
16:50
to
18:20
Knowledge market 3 (K3)
Tom Kugener
Oral presentation
4. Neural response to reward anticipation after acute exposure to cannabis with and without cannabidiol in adults and adolescents
16:50
to
18:20
Knowledge market 2 (K2)
Martine Skumlien
Oral presentation
E-cigarette use and conventional cigarette smoking among high school students in 35 European countries: findings from the 2019 ESPAD survey
16:50
to
18:20
Knowledge market 3 (K3)
Sonia Cerrai
Oral presentation
5. Acute effects of four CBD:THC ratios on attentional bias to cannabis and food cues: a randomized, double-blind, crossover study
16:50
to
18:20
Knowledge market 2 (K2)
Dominic Oliver
Oral presentation
Laughing gas (N2O) in The Netherlands: where a quick rise in use required action
16:50
to
18:20
Knowledge market 3 (K3)
Desiree Spronk
Oral presentation
Identifying subgroups of Dutch cannabis users based on help-seeking preferences: a latent class analysis
16:50
to
18:20
Knowledge market 3 (K3)
Marleen Olthof
Oral presentation
A National Recovery Study in Higher Education Institutions in Ireland
16:50
to
18:20
Knowledge market 3 (K3)
Ivers Jo-Hanna
Oral presentation
2. Motivational Interviewing for CUD: current situation and gaps
16:50
to
18:20
Knowledge market 4 (K4)
Hugo López Pelayo
Oral presentation
3. Cultural and language adaptation to Spanish of CANnabis DISorder Program (CANDIS)
16:50
to
18:20
Knowledge market 4 (K4)
Pablo Guzmán
Oral presentation
4. Pros and Cons of Group Therapy for Cannabis Use Disorders: Is it an opportunity for cultural adaptation?
16:50
to
18:20
Knowledge market 4 (K4)
Mercè Balcells
Oral presentation
Ayahuasca-assisted addiction treatment in Peru: qualitative results from a multi-year, mixed-methods study
16:50
to
18:20
Central square 3 (C3)
Olivia Marcus
Oral presentation
EXtended-release Pharmacotherapy for Opioid Use Disorder (EXPO)
16:50
to
18:20
Central square 3 (C3)
John Marsden
Oral presentation
1. Assisting drug policies in the quest for an evidence-base: challenges related to the development of a National Action Plan for the Drug Information System
16:50
to
18:20
Networking zone 2 (N2)
Viktor Mravcik
Oral presentation
Characteristics of concerned persons (CPs) accessing treatment services in their own right: A secondary analysis of Irish health data for 2010-2020.
16:50
to
18:20
Central square 3 (C3)
Cathy Kelleher
Oral presentation
2. Shared responsibilities among different stakeholders in the quest for evidence: experiences from Georgia
16:50
to
18:20
Networking zone 2 (N2)
Ketevan Sarajishvili
Oral presentation
6. European Prevention Curriculum – a tool for disseminating effective modern prevention approaches and facilitating well-informed choices about funding and implementation priorities: reflections from Georgia
16:50
to
18:20
Networking zone 2 (N2)
Jana D. Javakhishvili
Oral presentation
3. Capacity building for practitioners on evidence-based drug treatment interventions aligned with EU quality standards and tailored to national needs
16:50
to
18:20
Networking zone 2 (N2)
Anna Tarján
Oral presentation
4. Capacity building for practitioners on evidence-based drug treatment interventions aligned with EU quality standards and tailored to national needs: reflections from Georgia
16:50
to
18:20
Networking zone 2 (N2)
David Otiashvili
Oral presentation
5. The importance of an evidence-based approach in the development of a national drug policy
16:50
to
18:20
Networking zone 2 (N2)
Artur Malczewski
Oral presentation
1. Pharmacological treatments for cannabis use disorder
16:50
to
18:20
Knowledge market 4 (K4)
Albert Batalla
Oral presentation
2. Characteristics associated with drug use during the current detention – results from prison surveys in 4 EU countriessurveys in 4 EU countries
16:50
to
18:20
Central square 1 (C1)
Els Plettinckx
Oral presentation
5. Social determinants, health service contacts and incarceration among all those dying from an accidental overdose 2010-2018 in Norway
16:50
to
18:20
Central square 1 (C1)
Ellen J. Amundsen
Oral presentation
3. Reimprisonment rates among men who inject drugs in Victoria, Australia
16:50
to
18:20
Central square 1 (C1)
Ashleigh C. Stewart
Oral presentation
4. Adverse childhood experiences, substance use, and involvement with correctional services
16:50
to
18:20
Central square 1 (C1)
Richard Pates
Oral presentation
6. Wasted': the complex trajectories from incarceration to recovery. A personal experience
16:50
to
18:20
Central square 1 (C1)
Mark Johnson Ferguson
Oral presentation
1. Use pathways in prison. A French literature review
16:50
to
18:20
Central square 1 (C1)
Caroline Protais
Oral presentation
Signals from the future: Exploring implications for drug policies
16:50
to
18:20
Central square 4 (C4)
Laura Smit-rigter
18:30
Oral presentation
3. HCV treatment uptake among marginalized people who inject drugs in Norway: A registry-based study, and the Progress towards elimination of hepatitis C among people who inject drugs in Norway
18:30
to
19:30
Knowledge market 4 (K4)
Knut Boe Kielland
Oral presentation
2. Opportunistic Treatment of Hepatitis C Virus Infection: A pragmatic stepped-wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs (OPPORTUNI-C)
18:30
to
19:30
Knowledge market 4 (K4)
Olav Dalgard
Oral presentation
1. Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program. And new models to reach those hard to reach; results from Point of Care testing and treatment in a nurse led and a peer led mobile clinic
18:30
to
19:30
Knowledge market 4 (K4)
Linda Wüsthoff
Friday, 25 November
09:00
Oral presentation
An exploratory analysis of actigraphy and sleep diaries in a methamphetamine withdrawal clinical trial
09:00
to
10:30
Central square 2 (C2)
Liam Acheson
Oral presentation
Recovery and substitute addictions
09:00
to
10:30
Central square 2 (C2)
Deborah Louise Sinclair
Oral presentation
Determinants of recovery capital among persons in early and stable recovery from drug addiction
09:00
to
10:30
Central square 2 (C2)
Wouter Vanderplasschen
10:50
Oral presentation
3. Will they accept the vaccine? A 2021 COVID-19 survey among 477 people who use drugs in Norway
10:50
to
12:20
Insights zone 4 (I4)
Gabrielle K. Welle-Strand
Oral presentation
1. Revised service delivery of opioid agonist treatment in Norway in 2021, the second year of the pandemic: a national cross-sectional study of treatment provider experiences
10:50
to
12:20
Insights zone 4 (I4)
Anne Berit Bech
Oral presentation
4. Have predictors of drug addiction relapse changed during the COVID-19 pandemic? A prospective study of recovery pathways in the Netherlands, Belgium and UK
10:50
to
12:20
Insights zone 4 (I4)
Thomas Martinelli
Oral presentation
5. The impacts of COVID-19 pandemic on drug purchasing behaviours of people who use methamphetamine in Victoria, Melbourne.
10:50
to
12:20
Insights zone 4 (I4)
Kasun Rathnayake
Oral presentation
2. A rapid assessment of take-home naloxone provision during COVID-19 in Europe
10:50
to
12:20
Insights zone 4 (I4)
Rebecca Mc Donald
Oral presentation
What would it take to get people to stop rolling joints with tobacco?
10:50
to
12:20
Insights zone 2 (I2)
Adam Winstock
Oral presentation
Personas in drug use - Understanding substance-use motives in young adults
10:50
to
12:20
Insights zone 2 (I2)
Martha C de Jonge
Oral presentation
Data mining-based profiles of emerging adults at elevated risk for negative alcohol use consequences
10:50
to
12:20
Insights zone 2 (I2)
Elena Gervilla
Oral presentation
Strategic Ignorance or Counter Knowledge: 60 years of Harm Reduction Debates in Swedish Parliament
10:50
to
12:20
Insights zone 2 (I2)
Lena Eriksson
Oral presentation
1. Socioeconomic status, alcohol use and the mediating role of social support and neighbourhood disadvantage among individuals meeting criteria for a mental health problem: a cross-sectional study
10:50
to
12:20
Knowledge market 2 (K2)
Jo-Anne Puddephatt
Oral presentation
2. The association between mental health and alcohol use in racial and ethnic groups: A secondary data analysis across studies
10:50
to
12:20
Knowledge market 2 (K2)
Laura Goodwin
Oral presentation
3. Association of psychological distress with smoking cessation, duration of smoking abstinence and use of other nicotine-containing products: A cross-sectional population survey in Great Britain
10:50
to
12:20
Knowledge market 2 (K2)
Leonie Brose
Oral presentation
4. Can we make cannabis safer? An experimental study of four CBD: THC rations in healthy volunteers
10:50
to
12:20
Knowledge market 2 (K2)
Amir Englund
Oral presentation
Variations in the protective association between opioid agonist therapy and opioid overdose death by age and chronic disease status: findings from the OATS retrospective linked data study, NSW, Australia, 2001-2018.
10:50
to
12:20
Knowledge market 3 (K3)
Sarah Larney
Oral presentation
Temporal trend in the survival of injecting and non-injecting heroin-dependent patients admitted to treatment in Barcelona, Spain: a 30-year cohort study.
10:50
to
12:20
Knowledge market 3 (K3)
Anna Hernández-Rubio
Oral presentation
The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018.
10:50
to
12:20
Knowledge market 3 (K3)
Nicola Jones
Oral presentation
Increased risk of non-fatal overdose associated with NPS-type [‘street’] benzodiazepine use in Scotland, UK
10:50
to
12:20
Knowledge market 3 (K3)
Andrew McAuley
Oral presentation
The development of a disclaimer to accompany marketing and recruitment efforts for gambling products
10:50
to
12:20
Insights zone 3 (I3)
Anouk Tuijnman
Oral presentation
An online gambling intervention using the realization effect
10:50
to
12:20
Insights zone 3 (I3)
Ke Zhang
Oral presentation
Consumer Protection and Responsible Gambling Practices in Crypto Casinos
10:50
to
12:20
Insights zone 3 (I3)
Steve Sharman
Oral presentation
The utility of different values frameworks for drug policy analysis
10:50
to
12:20
Knowledge market 1 (K1)
Alison Ritter
Oral presentation
Why did New Zealand’s referendum to legalise recreation cannabis fail? An analysis of media campaigns and predictors of voter support for cannabis legalisation in New Zealand
10:50
to
12:20
Knowledge market 1 (K1)
Marta Rychert
Oral presentation
Language matters and it starts with us: How to talk about drugs to advocate for reform more effectively
10:50
to
12:20
Knowledge market 1 (K1)
Alice Salomon
Oral presentation
The Policy Constellation Approach: application of a critical realist public policy theory to the explanation of the UK’s drug strategy for 2021-2031
10:50
to
12:20
Knowledge market 1 (K1)
Alex Stevens
Oral presentation
Drug use and harm reduction in techno parties: some lessons learned from 20 years of fieldwork
10:50
to
12:20
Central square 3 (C3)
Fabrice Guilbaud
Oral presentation
New psychoactive substances tested by Energy Control, a community-based service of drug-checking and harm-reduction in Spain
10:50
to
12:20
Central square 3 (C3)
Adrià Quesada
Oral presentation
5. Drug use among non-binary persons in Europe: findings from a web survey
10:50
to
12:20
Networking zone 3 (N3)
Cristiana Vale Pires
Oral presentation
1. What is gender and why it is necessary to incorporate a gender perspective in the drug field? Evolution of key theoretical concepts in the area of gender and trends influencing the drug field
10:50
to
12:20
Networking zone 3 (N3)
Analia Torres
Oral presentation
2. Gender differences in drug use from a social perspective
10:50
to
12:20
Networking zone 3 (N3)
Nuria Romo
Oral presentation
3. Sex differences in drug use and drug addiction from a neuroscience perspective
10:50
to
12:20
Networking zone 3 (N3)
Anne Marije Kaag
Oral presentation
4. Using an intersectional risk environment approach to understand health and drug outcomes: Looking across social locations
10:50
to
12:20
Networking zone 3 (N3)
Alexandra B. Collins
Oral presentation
6. Implementing a gender dimension in drug policy and practice: findings from the Pompidou Group handbook for practitioners and decision makers
10:50
to
12:20
Networking zone 3 (N3)
Sarah Morton
Oral presentation
Size Matters: Comparing the MDMA content and weight of ecstasy tablets submitted to European drug checking services in 2012-2021
10:50
to
12:20
Central square 3 (C3)
Ruben Vrolijk
Oral presentation
Shifting stages of ATS use and evidence-based intervention for risk reduction
10:50
to
12:20
Central square 3 (C3)
Nienke Liebregts
Oral presentation
Polydrug use typologies of regular ecstasy users visiting electronic dance music events in the United Kingdom and the Netherlands: A Latent Class Analysis.
10:50
to
12:20
Central square 3 (C3)
Ruben Van Beek
Oral presentation
4. Drug consumption rooms in Lisbon: lessons learned
10:50
to
12:20
Central square 2 (C2)
Adriana Curado
Oral presentation
5. A strategy for all drug uses
10:50
to
12:20
Central square 2 (C2)
Maria Carmo Carvalho
Oral presentation
Factors associated with mortality in The Norwegian Offender Mental Health and Addiction (NorMA)- cohort
10:50
to
12:20
Central square 1 (C1)
Torill Tverborgvik
Oral presentation
All cause and cause specific mortality among individuals imprisoned for driving under the influence of alcohol and drugs in Norway (2000-2016)
10:50
to
12:20
Central square 1 (C1)
Ragnhild Jamt
Oral presentation
The Impact of Co-Occurring Mental Health Problems on Referral to and Initiation of Treatment Among Youth Under Probation Supervision
10:50
to
12:20
Central square 1 (C1)
Steven Belenko
Oral presentation
(Ex-)inmates' substance use: a needs assessment based on semi-structured interviews
10:50
to
12:20
Central square 1 (C1)
Nicky Dirkx
Oral presentation
Prevalence of heroin drug use before and during imprisonment in Europe: results from a comprehensive literature review and analysis of prevalence data in six European countries
10:50
to
12:20
Central square 1 (C1)
Sara Mazzilli
Oral presentation
3. Harm Reduction and Public Health: The place of 'subjugated knowledges'
10:50
to
12:20
Central square 2 (C2)
Daniel Martins
Oral presentation
1. How to reduce drug-related crimes
10:50
to
12:20
Central square 2 (C2)
Jorge Quintas
Oral presentation
2. 20 years of Portuguese drug policy: developments and current challenges
10:50
to
12:20
Central square 2 (C2)
Ximene Rêgo
Oral presentation
The needs of professionals working on sexualized substance use and its implications for health and social services
10:50
to
12:20
Knowledge market 4 (K4)
Jorge Flores-Aranda
Oral presentation
PnP/CHEMSEX a means of surviving post-migration
10:50
to
12:20
Knowledge market 4 (K4)
Alexandre Brulotte
Oral presentation
Don’t cure, but care': affirmative intervention amongst men of sexual and gender diversity in the context of chemsex
10:50
to
12:20
Knowledge market 4 (K4)
Yannick Gaudette
Oral presentation
Identity matters in understanding gay and bisexual men's injecting drug use: a grounded theory study
10:50
to
12:20
Knowledge market 4 (K4)
Sophia Elvira Schroeder
Oral presentation
Interpersonal needs of gay, bisexual, and other msm who practice sexualized substance use: a critical component in treating substance use disorders among sexual minorities
10:50
to
12:20
Knowledge market 4 (K4)
Joseph De Piano
Oral presentation
1. An insight into alcohol, tobacco, drug, gambling and gaming in the Mediterranean Region: socioeconomic, policy context and patterns of use among adolescents
10:50
to
12:20
Networking zone 4 (N4)
Elisa Benedetti
Oral presentation
2. Gaming, gambling and social media use among Egyptian adolescents
10:50
to
12:20
Networking zone 4 (N4)
Nermin Shaker
Oral presentation
3. Adolescent substance use and risk behaviours in Morocco: results and indications for prevention
10:50
to
12:20
Networking zone 4 (N4)
Jallal Toufiq
Oral presentation
4. Gender differences and trends in substance use among Tunisian adolescent students
10:50
to
12:20
Networking zone 4 (N4)
Hajer Aounallah-Skhiri
Oral presentation
2. Changing risk perception on alcohol consumption
10:50
to
12:20
Main stage
Carina Ferreira-Borges
Oral presentation
3. The Gut-Brain Axis in AUD - still valid?
10:50
to
12:20
Main stage
Philippe de Timary
Oral presentation
1. Presentation of the project "Alcohol no ordinary commodity (ANOC) vx 3"
10:50
to
12:20
Main stage
Jürgen Rehm
Oral presentation
Optimising digital tools for substance use and substance use disorders by 2030: a backcasting exercise
10:50
to
12:20
Insights zone 1 (I1)
Elsa Caballeria,
AbuTaher AbuTaher,
Florian Scheibein
Oral presentation
European Web Survey on Drugs
10:50
to
12:20
Central square 4 (C4)
João Matias,
José Pedro Teixeira
Oral presentation
European Web Survey on Drugs - Luxembourg
10:50
to
12:20
Central square 4 (C4)
Rita Cardoso Seixas
Oral presentation
European Web Survey on Drugs - Ireland
10:50
to
12:20
Central square 4 (C4)
Nicki Killeen
Oral presentation
The experience of running web surveys in Belgium
10:50
to
12:20
Central square 4 (C4)
Elena Damian
Oral presentation
Web surveys on drugs - how can these be important for those who use drugs
10:50
to
12:20
Central square 4 (C4)
Lígia Parodi
13:20
Oral presentation
Monitoring online illicit drug market during the COVID-19 in Georgia
13:20
to
14:50
Insights zone 4 (I4)
Irma Kirtadze
Oral presentation
Who buys drugs using online sources in Ireland? Findings from the European Web Survey on Drugs
13:20
to
14:50
Insights zone 4 (I4)
Deirdre Mongan
Oral presentation
Brokered Illegal Drug Sales as a Measure of Local Demand
13:20
to
14:50
Insights zone 4 (I4)
Georgiy Bobashev
Oral presentation
1. EU Xchange prevention registry: targeting common risk factors as a win-win in drug and crime prevention
13:20
to
14:50
Insights zone 2 (I2)
Charlotte De Kock
Oral presentation
4. Promoting professional behaviour change in prevention and health promotion
13:20
to
14:50
Insights zone 2 (I2)
Maximilian von Heyden
Oral presentation
3. Positive youth development as an agenda for cross-domain prevention: a scoping review of concepts, methods, and effects
13:20
to
14:50
Insights zone 2 (I2)
Samuel Tomczyk
Oral presentation
Hazardous, harmful and dependent alcohol use in Crisis Resolution Team patients: relationship with death or service recontact after a suicidal crisis.
13:20
to
14:50
Knowledge market 2 (K2)
John Robins
Oral presentation
Comparing characteristics of suicide to non-suicide drug poisoning, by sex, in Ireland.
13:20
to
14:50
Knowledge market 2 (K2)
Ena Lynn
Oral presentation
Characteristics associated with suicide among people who use drugs in Ireland 2015 to 2017: a repeated cross-sectional study
13:20
to
14:50
Knowledge market 2 (K2)
Suzi Lyons
Oral presentation
Implementation of a community-based psychiatric intervention among people who inject drugs in the City of Haiphong, Vietnam: the DRIVE-Mind project
13:20
to
14:50
Knowledge market 2 (K2)
Laurent Michel
Oral presentation
The impact of detoxification on suicidal behaviour among heroin users: longitudinal data from South Africa
13:20
to
14:50
Knowledge market 2 (K2)
Nirvana Morgan
Oral presentation
4. Understanding the mechanisms that link childhood stress with risk of addiction
13:20
to
14:50
Central square 4 (C4)
Molly Carlyle
Oral presentation
5. Is opioid liking driven by relief or reward? Evidence from clinical and experimental studies of acute stress
13:20
to
14:50
Central square 4 (C4)
Isabell M. Meier
Oral presentation
1. Cue-induced cocaine craving enhances psychosocial stress and vice versa in chronic cocaine users
13:20
to
14:50
Central square 4 (C4)
Boris Quednow
Oral presentation
2. The endocannabinoid system and drug addiction: basal and stress-related endocannabinoid plasma levels in chronic cocaine users and prescription opioid users
13:20
to
14:50
Central square 4 (C4)
Sara Kroll
Oral presentation
3. The endocannabinoid system as a potential buffer against the development of a substance use disorder following childhood trauma exposure
13:20
to
14:50
Central square 4 (C4)
Leah M. Mayo
Oral presentation
Seven years with take-home naloxone for overdose prevention in Norway: who are the first responders and how do they perform?
13:20
to
14:50
Knowledge market 3 (K3)
Øystein Bruun Ericson
Oral presentation
Post-Overdose Outreach Programs in Massachusetts: Lessons Learned, Impact and Best Practice Guidance
13:20
to
14:50
Knowledge market 3 (K3)
Alexander Walley
Oral presentation
The impact of the WHO/UNODC S-O-S training package on opioid overdose response knowledge and attitudes
13:20
to
14:50
Knowledge market 3 (K3)
Paul Dietze
Oral presentation
Binge drug injection among people who inject drugs in Montreal: characterizing the substances and social contexts involved to inform overdose prevention efforts
13:20
to
14:50
Knowledge market 3 (K3)
Nanor Minoyan
Oral presentation
Cannabis regulation and fiscal policy: Opportunities for human rights in Colombia
13:20
to
14:50
Knowledge market 1 (K1)
Luis Felipe Cruz-olivera
Oral presentation
Prioritising measures to assess performance of drug treatment services: perspectives of funders, treatment providers and service users
13:20
to
14:50
Knowledge market 1 (K1)
Robert Stirling
Oral presentation
Tracking the illicit Cannabis Market during the closed Cannabis Supply Chain Experiment in Netherlands using an online Crowdsourcing Approach
13:20
to
14:50
Knowledge market 1 (K1)
Stijn Hoorens
Oral presentation
Triangulating wastewater and a prospective survey of drug consumption – new insights for policy makers
13:20
to
14:50
Knowledge market 1 (K1)
Caitlin Hughes
Oral presentation
2. Hepatitis C and HIV associated risk factors among people in prison in Latvia, Lithuania, Portugal, Spain: informing interventions to prevent communicable diseases in prison setting
13:20
to
14:50
Main stage
Laura Isajeva
Oral presentation
The effects of cannabis liberalization laws on health, safety, and socioeconomic outcomes: An evidence and gap map
13:20
to
14:50
Knowledge market 1 (K1)
Eric Sevigny
Oral presentation
3. The international guidance on harm reduction interventions in prisons
13:20
to
14:50
Main stage
Ehab Salah
Oral presentation
5. Harm reduction interventions and viral hepatitis elimination in prison: models of care and barriers for implementation
13:20
to
14:50
Main stage
Lara Tavoschi
Oral presentation
4. Impact, role, and prevalence of medication assisted treatment (MAT) for opioid users in European prisons
13:20
to
14:50
Main stage
Heino Stöver
Oral presentation
1. Provision of harm reduction interventions in European prisons: short overview of available services
13:20
to
14:50
Main stage
Linda Montanari
Oral presentation
Substance-related Consequences, Dependence and Substance Use Disorder: Promising new model taking clinical and statistical points of view into consideration
13:20
to
14:50
Central square 1 (C1)
Rosalie Genois
Oral presentation
3. Navigating an emergency response and collective action on the fentanyl frontlines: An ethnographic study of overdose prevention site implementation in Vancouver, Canada’s Downtown Eastside
13:20
to
14:50
Central square 2 (C2)
Ryan McNeil
Oral presentation
1. Drug consumption rooms: welfare state and social acceptance in France
13:20
to
14:50
Central square 2 (C2)
Marie Jauffret-Roustide
Oral presentation
2. Drug consumption rooms in Denmark: attitudes and experiences from local residents
13:20
to
14:50
Central square 2 (C2)
Esben Houborg
Oral presentation
Prevention and Treatment of hazardous Substance Use among Refugees: Perspectives from Germany
13:20
to
14:50
Central square 3 (C3)
Marion Laging
Oral presentation
Psychosocial functions of drug using and selling among young persons in Malmö who came to Sweden as unaccompanied refugee minors
13:20
to
14:50
Central square 3 (C3)
Anke Stallwitz
Oral presentation
Re-visioning from risk and safety to survival and wellness; behaviours among people who use methamphetamine with opioids in British Columbia, Canada
13:20
to
14:50
Central square 3 (C3)
Jessica Xavier
Oral presentation
Indigenous Peoples experiences with overdose and response in Vancouver, Canada's Downtown Eastside
13:20
to
14:50
Central square 3 (C3)
Jennifer Lavalley
Oral presentation
Language and concepts in alcohol use disorder: how framing affects stigma and recovery
13:20
to
14:50
Central square 1 (C1)
James Morris
Oral presentation
Watch out for the boogieman': multiple stigma and recovery experiences of ethnic minorities with substance use problems
13:20
to
14:50
Central square 3 (C3)
Aline Pouille
Oral presentation
Drinking patterns across Europe. Do beverage preferences matter?
13:20
to
14:50
Central square 1 (C1)
Janusz Sieroslawski
Oral presentation
Emerging Issues in the Management of Conflict of Interest
13:20
to
14:50
Central square 1 (C1)
Matej Košir
Oral presentation
Reproducibility and translation in addiction research
13:20
to
14:50
Central square 1 (C1)
Rainer Spanagel
Oral presentation
2. The experience of persons in homeless situation with alcohol related problems regarding a pharmacological harm reduction initiative
13:20
to
14:50
Knowledge market 4 (K4)
Raquel Medinas
Oral presentation
4. The role of those without a role - The perspective of non-clinical professionals in emergencyshelters on how to manage alcohol use disorder - police, security agents and cleaning staff
13:20
to
14:50
Knowledge market 4 (K4)
Ricardo Fuertes
Oral presentation
3. Amidst the most vulnerable voices: women and migrants in homeless situation with Alcohol UseDisorders (AUD)
13:20
to
14:50
Knowledge market 4 (K4)
Màrio Santos
Oral presentation
1. A novel way of enhancing adherence to acamprosate for alcohol dependence: The Alcohol Dependence and Adherence to Medicine (ADAM) trial
13:20
to
14:50
Networking zone 3 (N3)
Thomas Phillips
Oral presentation
5. All we can do - Emergency Shelter' staff positioning regarding alcohol related problems in thecontext of a new harm reduction intervention
13:20
to
14:50
Knowledge market 4 (K4)
Joana Tavares
Oral presentation
2. Effectiveness and cost-effectiveness of face-to-face and electronic brief interventions versus screening alone to reduce alcohol consumption among high-risk adolescents presenting to Emergency Departments: three-arm pragmatic randomised trial
13:20
to
14:50
Networking zone 3 (N3)
Paolo Deluca
Oral presentation
3. Alcohol Assertive Outreach Treatment randomised controlled trial: a mixed methods economic evaluation
13:20
to
14:50
Networking zone 3 (N3)
Amy Wolstenholme
Oral presentation
1. Individuals with lived experience of homelessness and alcohol use disorders - insights from the PLACE study
13:20
to
14:50
Knowledge market 4 (K4)
Ana Neto